iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
December 22 2021 - 9:25AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a
developer of next-generation biopharmaceuticals and pioneer of the
sustainable,
plant-based
FastPharming Manufacturing
System®, today announced that it has adjourned its 2021
Annual Meeting of Shareholders (the “Annual Meeting”) with respect
to Proposals 4 and 5.
The Company partially adjourned the Annual
Meeting on December 9, 2021 with respect to Proposal 4 (Reverse
Stock Split) and Proposal 5 (Change in Authorized Shares) to allow
those stockholders who hold approximately 40% of the unvoted shares
more time to vote. iBio subsequently received additional votes
“FOR” the proposals, as well as support from a number of
shareholders who changed their “against” votes. Given that voting
is still trending in favor of these proposals, the Company has
adjourned the reconvened Annual Meeting to provide its shareholders
additional time to vote. The Annual Meeting will resume with
respect to Proposal 4 and 5 at 9:00 a.m. Eastern time on January
31, 2022 and can be accessed at
www.virtualshareholdermeeting.com/IBIO2021.
If you have already voted your shares
“FOR” Proposals 4 and 5, we thank you. If you did not yet vote,
abstained, or voted against, we kindly ask you to vote, or to
reconsider your vote.
For additional information on the Proposals, please
see our Shareholder Vote FAQ.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines vertical
farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
antigens, and other proteins. iBio is developing proprietary
biopharmaceuticals for the treatment of cancers, as well as
fibrotic and infectious diseases. The Company’s wholly-owned
subsidiary, iBio CDMO LLC, provides FastPharming
Contract Development and Manufacturing Services along with
Glycaneering Development Services™ for advanced
recombinant protein design. For more information,
visit www.ibioinc.com. Contact:
Stephen Kilmer iBio, Inc. Investor
Relations (646) 274-3580 skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024